FDA OKs Thermo Fisher’s companion diagnostic for 3 NSCLC treatments

Thermo Fisher headquarters
Thermo Fisher's Oncomine test is the first NSCLC companion diagnostic that screens for multiple biomarkers at a time, which can reduce the amount of time it takes to match a patient to the appropriate treatment.

Thermo Fisher earned FDA premarket approval for its companion diagnostic that screens tumors for biomarkers associated with three non-small cell lung cancer (NSCLC) treatments and can help identify patients who are suitable for treatment with one of these therapies.

The Oncomine Dx Target Test is the first companion diagnostic that simultaneously assesses a patient’s eligibility for treatment with multiple NSCLC therapies, Thermo Fisher said in a statement.

The test, which evaluates 23 genes associated with NSCLC, may be used to determine which patients would benefit from treatment with Pfizer’s Xalkori, AstraZeneca’s Iressa, or Novartis’ combo treatment, Tafinlar and Mekinist.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Other companion diagnostics, such as Roche’s test for Xalkori, evaluate tumors one biomarker at a time. Because it evaluates tumors for responsiveness to three treatments simultaneously, the Oncomine test can cut down the amount of time it takes to match patients to therapies. Physicians may be able to do this in days rather than several weeks, Thermo Fisher said.

"For people battling non-small cell lung cancer, time is critical and days matter," said Joydeep Goswami, president of clinical next-generation sequencing and oncology at Thermo Fisher. "The Oncomine Dx Target Test rapidly guides oncologists toward the right targeted therapy, with the goal of improving patient outcomes and the cost-efficiency of treatments."

Lung cancer is the second most common cancer and the leading cause of cancer death in the U.S. But the company isn’t stopping here.

"Thermo Fisher has entered into discussions with several pharmaceutical companies looking to use the panel for FDA-approved targeted therapy applications beyond lung cancer," Goswami added. "Expanding the range of clinically actionable information is part of the company's goal to help our customers advance precision medicine."

Suggested Articles

The FDA has cleared its first duodenoscope designed to make the intricate, moving and difficult-to-clean parts in the head of the device disposable.

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

Novartis tapped Biofourmis to develop tracking programs for heart failure patients, as the latter acquired Biovotion, makers of clinical wearables.